India’s pharmaceutical sector is projected to experience an 11% year-on-year growth in sales and EBITDA for Q1 FY26, driven by strong market performance across various regions. The hospital segment is expected to lead with a 17% growth, while diagnostics firms anticipate a 14% sales increase. Government initiatives and investments in R&D further support the industry’s optimistic outlook.